Structure-based design of selective histone deacetylase 6 zinc binding groups

References

• Amin, S. A., Adhikari, N., Jha, T., & Ghosh, B. (2019). Designing potential HDAC3 inhibitors to improve memory and learning. Journal of Biomolecular Structure and Dynamics, 37(8), 2133–2142. doi: 10.1080/07391102.2018.1477625
   PubMed Web of Science ®Google Scholar
• Baroni, M., Cruciani, G., Sciabola, S., Perruccio, F., & Mason, J. S. (2007). A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for ligands and proteins (FLAP): Theory and application. Journal of Chemical Information and Modeling, 47(2), 279–294. doi: 10.1021/ci600253e
   PubMed Web of Science ®Google Scholar
• Batchu, S. N., Brijmohan, A. S., & Advani, A. (2016). The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease. Clinical Science, 130(12), 987–1003. doi: 10.1042/CS20160084
   PubMed Web of Science ®Google Scholar
• Bergman, J. A., Woan, K., Perez-Villarroel, P., Villagra, A., Sotomayor, E. M., & Kozikowski, A. P. (2012). Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. Journal of Medicinal Chemistry, 55(22), 9891–9899. doi: 10.1021/jm301098e
   PubMed Web of Science ®Google Scholar
• Bressi, J. C., Jennings, A. J., Skene, R., Wu, Y., Melkus, R., Jong, R. D., O’Connell, S., Grimshaw, C. E., Navre, M., & Gangloff, A. R. (2010). Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-Aminophenyl)benzamides. Bioorganic & Medicinal Chemistry Letters, 20(10), 3142–3145. doi: 10.1016/j.bmcl.2010.03.091
   PubMed Web of Science ®Google Scholar
• Bürli, R. W., Luckhurst, C. A., Aziz, O., Matthews, K. L., Yates, D., Lyons, K. A., … Dominguez, C. (2013). Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington’s disease. Journal of Medicinal Chemistry, 56(24), 9934–9954. doi: 10.1021/jm4011884
   PubMed Web of Science ®Google Scholar
• Chem Axon. (2017a). Instant JChem V17.3.27.0. Retrieved from https://chemaxon.com/products/instant-jchem.
   Google Scholar
• Chem Axon. (2017b). Marvin Sketch V17.27. Retrieved from https://chemaxon.com/products/marvin.
   Google Scholar
• Chen, K., Xu, L., & Wiest, O. (2013). Computational exploration of zinc binding groups for HDAC inhibition. The Journal of Organic Chemistry, 78(10), 5051–5055. doi: 10.1021/jo400406g
   PubMed Web of Science ®Google Scholar
• Cohen, S. M. (2017). A bioinorganic approach to fragment-based drug discovery targeting metalloenzymes. Accounts of Chemical Research, 50(8), 2007–2016. doi: 10.1021/acs.accounts.7b00242
   PubMed Web of Science ®Google Scholar
• Congreve, M., Carr, R., Murray, C., & Jhoti, H. (2003). A ‘rule of three’ for fragment-based lead discovery? Drug Discovery Today, 8(19), 876–877. doi: 10.1016/S1359-6446(03)02831-9
   PubMed Web of Science ®Google Scholar
• Cruciani, G. (2006). Molecular interaction fields: Applications in drug discovery and ADME prediction. Hoboken, NJ: Wiley-VCH. Retrieved from https://www.wiley.com/en-us/Molecular+Interaction+Fields%3A+Applications+in+Drug+Discovery+and+ADME+Prediction-p-9783527607136.
   Google Scholar
• Dassault Systèmes BIOVIA. (2016). Discovery Studio v.17.2.0. Retrieved from https://www.3dsbiovia.com/products/collaborative-science/biovia-discovery-studio/visualization-download.php.
   Google Scholar
• de Ruijter, A. J. M., van Gennip, A. H., Caron, H. N., Kemp, S., & van Kuilenburg, A. B. P. (2003). Histone Deacetylases (HDACs): Characterization of the Classical HDAC Family. The Biochemical Journal, 370(3), 737–749. doi: 10.1042/bj20021321
   PubMedGoogle Scholar
• Eldridge, M. D., Murray, C. W., Auton, T. R., Paolini, G. V., & Mee, R. P. (1997). JCAMD_1997_11_425_Eldridge. 11: 1–21. papers3://publication/uuid/EDB550EA-F218-4741-A298-02AF9CCB2D57.
   Google Scholar
• Fass, D. M., Shah, R., Ghosh, B., Hennig, K., Norton, S., Zhao, W.-N., … Haggarty, S. J. (2011). Short-chain HDAC inhibitors differentially affect vertebrate development and neuronal chromatin. ACS Medicinal Chemistry Letters, 2(1), 39–42. doi: 10.1021/ml1001954
   Web of Science ®Google Scholar
• Gaulton, A., Hersey, A., Nowotka, M., Bento, A. P., Chambers, J., Mendez, D., … Leach, A. R. (2017). The ChEMBL database in 2017. Nucleic Acids Research, 45(D1), D945–D954. doi: 10.1093/nar/gkw1074
   PubMed Web of Science ®Google Scholar
• Giannini, G., Vesci, L., Battistuzzi, G., Vignola, D., Milazzo, F. M., Guglielmi, M. B., … Cabri, W. (2014). ST7612AA1, a thioacetate-ω(γ-lactam carboxamide) derivative selected from a novel generation of oral HDAC inhibitors. Journal of Medicinal Chemistry, 57(20), 8358–8377. doi: 10.1021/jm5008209
   PubMed Web of Science ®Google Scholar
• Goodford, P. J. (1985). A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. Journal of Medicinal Chemistry, 28(7), 849–857. doi: 10.1021/jm00145a002
   PubMed Web of Science ®Google Scholar
• Goracci, L., Deschamps, N., Randazzo, G. M., Petit, C., Dos Santos Passos, C., Carrupt, P.-A., Simões-Pires, C., & Nurisso, A. (2016). A rational approach for the identification of non-hydroxamate HDAC6-selective inhibitors. Scientific Reports, 6(1), 29086. doi: 10.1038/srep29086
   PubMedGoogle Scholar
• Hai, Y., & Christianson, D. W. (2016). Histone deacetylase 6 structure and molecular basis of catalysis and inhibition. Nature Chemical Biology, 12(9), 741–747. doi: 10.1038/nchembio.2134
   PubMed Web of Science ®Google Scholar
• Hermant, P., Bosc, D., Piveteau, C., Gealageas, R., Lam, B. V., Ronco, C., … Deprez-Poulain, R. (2017). Controlling plasma stability of hydroxamic acids: A MedChem toolbox. Journal of Medicinal Chemistry, 60(21), 9067–9089. doi: 10.1021/acs.jmedchem.7b01444
   PubMed Web of Science ®Google Scholar
• Homeyer, N., & Gohlke, H. (2012). Free energy calculations by the molecular mechanics Poisson-Boltzmann surface area method. Molecular Informatics, 31(2), 114–122. doi: 10.1002/minf.201100135
   PubMed Web of Science ®Google Scholar
• Ibrahim Uba, A., & Yelekçi, K. (2019). Homology modeling of human histone deacetylase 10 and design of potential selective inhibitors. Journal of Biomolecular Structure and Dynamics, 34(14). doi: 10.1080/07391102.2018.1521747
   PubMedGoogle Scholar
• Irwin, J. J., Sterling, T., Mysinger, M. M., Bolstad, E. S., & Coleman, R. G. (2012). ZINC: A free tool to discover chemistry for biology. Journal of Chemical Information and Modeling, 52(7), 1757–1768. doi: 10.1021/ci3001277
   PubMed Web of Science ®Google Scholar
• Jacobsen, J. A., Fullagar, J. L., Miller, M. T., & Cohen, S. M. (2011). Identifying chelators for metalloprotein inhibitors using a fragment-based approach. Journal of Medicinal Chemistry, 54(2), 591–602. doi: 10.1021/jm101266s
   PubMed Web of Science ®Google Scholar
• Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997). Development and validation of a genetic algorithm for flexible docking. Journal of Molecular Biology, 267(3), 727–748. doi: 10.1006/jmbi.1996.0897
   PubMed Web of Science ®Google Scholar
• Jones, P., Bottomley, M. J., Carfí, A., Cecchetti, O., Ferrigno, F., Lo Surdo, P., & Ontoria, J. M. (2008). 2-trifluoroacetylthiophenes, a novel series of potent and selective Class II histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters, 18(11), 3456–3461. doi: 10.1016/j.bmcl.2008.02.026
   PubMed Web of Science ®Google Scholar
• Kalin, J. H., & Bergman, J. A. (2013). Development and therapeutic implications of selective histone deacetylase 6 inhibitors. Journal of Medicinal Chemistry, 56(16), 6297–6313. doi: 10.1021/jm4001659
   PubMed Web of Science ®Google Scholar
• Kashyap, K., & Kakkar, R. (2019). An insight into Selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies. Journal of Biomolecular Structure and Dynamics, 1–18. doi: 10.1080/07391102.2019.1567388
   PubMed Web of Science ®Google Scholar
• Kawai, K., & Nagata, N. (2012). Metal–Ligand interactions: An analysis of zinc binding groups using the protein data bank. European Journal of Medicinal Chemistry, 51, 271–276. doi: 10.1016/j.ejmech.2012.02.028
   PubMed Web of Science ®Google Scholar
• Kemp, M. M., Wang, Q., Fuller, J. H., West, N., Martinez, N. M., Morse, E. M., Weïwer, M., Schreiber, S. L., Bradner, J. E., & Koehler, A. N. (2011). A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold. Bioorganic & Medicinal Chemistry Letters, 21(14), 4164–4169. doi: 10.1016/j.bmcl.2011.05.098
   PubMed Web of Science ®Google Scholar
• KrennHrubec, K., Marshall, B. L., Hedglin, M., Verdin, E., & Ulrich, S. M. (2007). Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors. Bioorganic & Medicinal Chemistry Letters, 17(10), 2874–2878. doi: 10.1016/j.bmcl.2007.02.064
   PubMed Web of Science ®Google Scholar
• Kutil, Z., Novakova, Z., Meleshin, M., Mikesova, J., Schutkowski, M., & Barinka, C. (2017). HDAC11 is a fatty-acid deacylase. ACS chemical biology, 13(36), 85–693.
   Google Scholar
• Lagorce, D., Sperandio, O., Baell, J. B., Miteva, M. A., & Villoutreix, B. O. (2015). FAF-Drugs3: A web server for compound property calculation and chemical library design. Nucleic Acids Research, 43(W1), W200–207. doi: 10.1093/nar/gkv353
   PubMed Web of Science ®Google Scholar
• Liang, T., & Fang, H. (2019). Structure, functions and selective inhibitors of HDAC6. Current Topics in Medicinal Chemistry, 18(28), 2429–2447. doi: 10.2174/1568026619666181129141822
   Web of Science ®Google Scholar
• Lindorff-Larsen, K., Piana, S., Palmo, K., Maragakis, P., Klepeis, J. L., Dror, R. O., & Shaw, D. E. (2010). Improved side-chain torsion potentials for the Amber Ff99SB protein force field. Proteins: Structure, Function, and Bioinformatics, 78(8), 1950–1958. doi: 10.1002/prot.22711
   PubMed Web of Science ®Google Scholar
• Frisch, M. J., Trucks, G. W., Schlegel, H. B., Scuseria, G. E., Robb, M. A., Cheeseman, J. R., … Fox, D. J. (2009). Gaussian 09, Revision D.01.
   Google Scholar
• Mahalakshmi, R., Husayn Ahmed, P., & Mahadevan, V. (2018). HDAC inhibitors show differential epigenetic regulation and cell survival strategies on P53 mutant colon cancer cells. Journal of Biomolecular Structure and Dynamics, 36(4), 938–955. doi: 10.1080/07391102.2017.1302820
   PubMed Web of Science ®Google Scholar
• Martin, D. P., Blachly, P. G., Marts, A. R., Woodruff, T. M., de Oliveira, C. A. F., McCammon, J. A., Tierney, D. L., & Cohen, S. M. (2014). Unconventional’ coordination chemistry by metal chelating fragments in a metalloprotein active site. Journal of the American Chemical Society, 136(14), 5400–5406. doi: 10.1021/ja500616m
   PubMed Web of Science ®Google Scholar
• Martínez-Rosell, G., Giorgino, T., & De Fabritiis, G. (2017). PlayMolecule ProteinPrepare: A web application for protein preparation for molecular dynamics simulations. Journal of Chemical Information and Modeling, 57(7), 1511–1516. doi: 10.1021/acs.jcim.7b00190
   PubMed Web of Science ®Google Scholar
• Mazitschek, R., Patel, V., Wirth, D. F., & Clardy, J. (2008). Development of a fluorescence polarization based assay for histone deacetylase ligand discovery. Bioorganic & Medicinal Chemistry Letters, 18(9), 2809–2812. doi: 10.1016/j.bmcl.2008.04.007
   PubMed Web of Science ®Google Scholar
• Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., & Olson, A. J. (1998). Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computational Chemistry, 19(14), 1639–1662. doi: 10.1002/(SICI)1096-987X(19981115)19:14 < 1639::AID-JCC10 > 3.0.CO;2-B
   Web of Science ®Google Scholar
• Murray-Thompson, M., Wu, Z., Reid, R. A., Soler, D., Nolan, M. A., Wright, Q. G., & Moyer, M. B. (2013). Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nature Chemical Biology, 9(5), 319–325. doi: 10.1038/nchembio.1223
   PubMed Web of Science ®Google Scholar
• Muthyala, R., Shin, W. S., Xie, J., & Sham, Y. Y. (2015). Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia. Bioorganic & Medicinal Chemistry Letters, 25(19), 4320–4324. doi: 10.1016/j.bmcl.2015.07.065
   PubMed Web of Science ®Google Scholar
• Olson, D. E., Wagner, F. F., Kaya, T., Gale, J. P., Aidoud, N., Davoine, E. L., Lazzaro, F., Weïwer, M., Zhang, Y.-L., & Holson, E. B. (2013). Discovery of the first histone deacetylase 6/8 dual inhibitors. Journal of Medicinal Chemistry, 56(11), 4816–4820. doi: 10.1021/jm400390r
   PubMed Web of Science ®Google Scholar
• Otava Chemicals. (2017). Otava chelator fragment library. Retrieved from http://www.otavachemicals.com/.
   Google Scholar
• Paissoni, C., Spiliotopoulos, D., Musco, G., & Spitaleri, A. (2015). GMXPBSA 2.1: A GROMACS tool to perform MM/PBSA and computational alanine scanning. Computer Physics Communications, 186, 105–107. doi: 10.1016/j.cpc.2014.09.010
   Google Scholar
• Pande, V. (2016). Understanding the complexity of epigenetic target space. Journal of Medicinal Chemistry, 59(4), 1299–1307. doi: 10.1021/acs.jmedchem.5b01507
   PubMed Web of Science ®Google Scholar
• Patil, V., Sodji, Q. H., Kornacki, J. R., Mrksich, M., & Oyelere, A. K. (2013). 3-hydroxypyridin-2-thione as novel zinc binding group for selective histone deacetylase inhibition. Journal of Medicinal Chemistry, 56(9), 3492–3506. doi: 10.1021/jm301769u
   PubMed Web of Science ®Google Scholar
• PerkinElmer. (2015). ChemDraw—Chemical drawing software, PerkinElmer. Retrieved from http://www.perkinelmer.com/category/chemdraw.
   Google Scholar
• Perruccio, F., Mason, J. S., Sciabola, S., & Baroni, M. (2006). FLAP: 4-point pharmacophore fingerprints from GRID. In Molecular interaction fields: Applications in drug discovery and ADME prediction (Vol. 27, pp. 83–102). Hoboken, NJ: Wiley. doi: 10.1073/pnas.1718823114
   Google Scholar
• Porter, N. J., Mahendran, A., Breslow, R., & Christianson, D. W. (2017). Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors. Proceedings of the National Academy of Sciences, 114(51), 13459–13464. doi: 10.1073/pnas.1718823114
   PubMed Web of Science ®Google Scholar
• Porter, N. J., Osko, J. D., Diedrich, D., Kurz, T., Hooker, J. M., Hansen, F. K., & Christianson, D. W. (2018). Histone deacetylase 6-selective inhibitors and the influence of capping groups on hydroxamate-zinc denticity. Journal of Medicinal Chemistry, 61(17), 8054–8060. doi: 10.1021/acs.jmedchem.8b01013
   PubMed Web of Science ®Google Scholar
• Porter, N. J., Wagner, F. F., & Christianson, D. W. (2018). Entropy as a driver of selectivity for inhibitor binding to histone deacetylase 6. Biochemistry, 57(26), 3916–3924. doi: 10.1021/acs.biochem.8b00367
   PubMed Web of Science ®Google Scholar
• Pronk, S., Páll, S., Schulz, R., Larsson, P., Bjelkmar, P., Apostolov, R., … Lindahl, E. (2013). GROMACS 4.5: A high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics, 29(7), 845–854. doi: 10.1093/bioinformatics/btt055
   PubMed Web of Science ®Google Scholar
• Roche, J., & Bertrand, P. (2016). Inside HDACs with more selective HDAC inhibitors. European Journal of Medicinal Chemistry, 121, 451–483. doi: 10.1016/j.ejmech.2016.05.047
   PubMed Web of Science ®Google Scholar
• Seidel, C., Schnekenburger, M., Dicato, M., & Diederich, M. (2015). Histone deacetylase 6 in health and disease. Epigenomics, 7(1), 103–118. doi: 10.2217/epi.14.69
   PubMed Web of Science ®Google Scholar
• Sharma, M., Jha, P., Verma, P., & Chopra, M. (2019). Combined comparative molecular field analysis, comparative molecular similarity indices analysis, molecular docking and molecular dynamics studies of histone deacetylase 6 inhibitors. Chemical Biology & Drug Design, 93(5), 910–925. doi: 10.1111/cbdd.13488
   PubMed Web of Science ®Google Scholar
• Shen, S., & Kozikowski, A. P. (2016). Why hydroxamates may not be the best histone deacetylase inhibitors—What some may have forgotten or would rather forget? ChemMedChem, 11(1), 15–21. doi: 10.1002/cmdc.201500486
   PubMed Web of Science ®Google Scholar
• Sixto-López, Y., Bello, M., & Correa-Basurto, J. (2019a). Insights into structural features of HDAC1 and its selectivity inhibition elucidated by molecular dynamic simulation and molecular docking. Journal of Biomolecular Structure and Dynamics, 37(3), 584–610. doi: 10.1080/07391102.2018.1441072
   PubMed Web of Science ®Google Scholar
• Sixto-López, Y., Bello, M., & Correa-Basurto, J. (2019b). Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6. Journal of Biomolecular Structure and Dynamics, 1–20. doi: 10.1080/07391102.2018.1557560
   PubMed Web of Science ®Google Scholar
• Søndergaard, C. R., Olsson, M. H. M., Rostkowski, M., & Jensen, J. H. (2011). Improved treatment of ligands and coupling effects in empirical calculation and rationalization of p K a values. Journal of Chemical Theory and Computation, 7(7), 2284–2295. doi: 10.1021/ct200133y
   PubMed Web of Science ®Google Scholar
• Sousa da Silva, A. W., & Vranken, W. F. (2012). ACPYPE—AnteChamber PYthon Parser InterfacE. BMC Research Notes, 5(1), 367. doi: 10.1186/1756-0500-5-367
   PubMedGoogle Scholar
• Uba, A. I., & Yelekçi, K. (2018). Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: A combined approach of structure-based virtual screening, admet prediction and molecular dynamics simulation assay. Journal of Biomolecular Structure and Dynamics, 36(12), 3231–3245. doi: 10.1080/07391102.2017.1384402
   PubMed Web of Science ®Google Scholar
• VanHeyst, M. D., Ononye, S. N., Wright, D. L., Ammar, M., Anderson, A. C., Zhou, W., & Oblak, E. Z. (2013). Tropolones as lead-like natural products: The development of potent and selective histone deacetylase inhibitors. ACS Medicinal Chemistry Letters, 4(8), 757–761. doi: 10.1021/ml400158k
   PubMed Web of Science ®Google Scholar
• Vassetti, D., Pagliai, M., & Procacci, P. (2019). Assessment of GAFF2 and OPLS-AA general force fields in combination with the water models TIP3P, SPCE, and OPC3 for the solvation free energy of druglike organic molecules. Journal of Chemical Theory and Computation, 15(3), 1983–1995. doi: 10.1021/acs.jctc.8b01039
   PubMed Web of Science ®Google Scholar
• Wagner, F. F., Olson, D. E., Jennifer, P. G., Kaya, T., Weïwer, M., Aidoud, N., & Thomas, M. (2013). Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif. Journal of Medicinal Chemistry, 56(4), 1772–1776. doi: 10.1016/j.ejmech.2017.10.040
   PubMed Web of Science ®Google Scholar
• Wagner, F. F., Lundh, M., Kaya, T., McCarren, P., Zhang, Y. L., Chattopadhyay, S., … & Vetere, A. (2016). An isochemogenic set of inhibitors to define the therapeutic potential of histone deacetylases in β-cell protection. ACS Chemical Biology, 11(2), 363–374. doi:10.1021/acschembio.5b00640.
   PubMed Web of Science ®Google Scholar
• Wang, X.-X., Wan, R.-Z., & Liu, Z.-P. (2018). Recent advances in the discovery of potent and selective HDAC6 inhibitors. European Journal of Medicinal Chemistry, 143, 1406–1418. doi: 10.1016/j.ejmech.2017.10.040
   PubMed Web of Science ®Google Scholar
• Wang, Y., Yang, L., Hou, J., Zou, Q., Gao, Q., Yao, W., … Zhang, J. (2019). Hierarchical virtual screening of the dual MMP-2/HDAC-6 inhibitors from natural products based on pharmacophore models and molecular docking. Journal of Biomolecular Structure and Dynamics, 37(3), 649–670. doi: 10.1080/07391102.2018.1434833
   PubMed Web of Science ®Google Scholar
• Watson, P. J., Millard, C. J., Riley, A. M., Robertson, N. S., Wright, L. C., Godage, H. Y., … Schwabe, J. W. R. (2016). Insights into the activation mechanism of class I HDAC complexes by inositol phosphates. Nature Communications, 7, 11262. doi: 10.1016/j.bmc.2011.06.030
   PubMed Web of Science ®Google Scholar
• Whitehead, L., Dobler, M. R., Radetich, B., Zhu, Y., Atadja, P. W., Claiborne, T., … Stams, T. (2011). Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors. Bioorganic & Medicinal Chemistry, 19(15), 4626–4634. doi: 10.1016/j.bmc.2011.06.030
   PubMed Web of Science ®Google Scholar
• Wu, J., Adejare, A., Wang, J., Wallach, J., Duane, S., Ma, H., Wang, Y., & Wang, Y. (2017). Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs. Drug Design, Development and Therapy, 11, 1369–1382. doi: 10.2147/DDDT.S124977
   PubMed Web of Science ®Google Scholar
• Yang, M., Robert Orlowski, P., Hari, S. S., Jones, R. J., Markelewicz, N., Raje, J. G., … Wheeler, C. (2017). Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Clinical Cancer Research, 23(13), 3307–3315. doi: 10.1158/1078-0432.CCR-16-2526
   PubMed Web of Science ®Google Scholar
• Yuan, Y., Hu, Z., Bao, M., Sun, R., Long, X., Long, L., … Bao, J. (2018). Screening of novel histone deacetylase 7 inhibitors through molecular docking followed by a combination of molecular dynamics simulations and ligand-based approach. Journal of Biomolecular Structure and Dynamics,37(15), 1–12. doi: 10.1080/07391102.2018.1541141
   PubMed Web of Science ®Google Scholar
• Zhou, H., Wang, C., Deng, T., Tao, R., & Li, W. (2018). Novel urushiol derivatives as HDAC8 inhibitors: Rational design, virtual screening, molecular docking and molecular dynamics studies. Journal of Biomolecular Structure and Dynamics, 36(8), 1966–1978. doi: 10.1080/07391102.2017.1344568
   PubMed Web of Science ®Google Scholar